News

November 9, 2018

Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests

News

Ovarian cancer patients who receive Zejula (niraparib) after responding to platinum-based chemotherapy experience fewer adverse effects in a real-world setting than was reported in a Phase 3 clinical trial, a study ... Read more

November 5, 2018

Adding GEN-1 to Standard Chemotherapy Halts Advanced Ovarian Cancer Progression, Phase 1b Trial Shows

News

A combination of Celsion’s DNA-based immunotherapy GEN-1 and standard chemotherapy halted disease progression in women with stage III/IV ovarian cancer eligible for surgery, according to results of a Phase 1b trial. The ... Read more

November 2, 2018

Compugen, Bristol-Myers Squibb Collaborating to Test COM701, Opdivo Combo for Ovarian, Other Cancers

News

Compugen has entered into a clinical trial collaboration with Bristol-Myers Squibb (BMS) to evaluate the safety and preliminary effectiveness of its investigational immunotherapy COM701 in combination with BMS’ Opdivo (nivolumab), in a ... Read more

October 29, 2018October 29, 2018

Cancer Cells from Fallopian Tube Communicate with Healthy Ovaries to Promote Cancer Growth, Researchers Find

News

Cancer cells from the fallopian tube — the precursors of ovarian cancer — communicate with healthy ovaries and trigger the release of a hormone called norepinephrine, creating an environment for ... Read more

October 26, 2018

Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients

News

The Phase 1a/1b trial evaluating Five Prime Therapeutics‘ checkpoint inhibitor FPA150 in patients with advanced solid cancers has begun dosing patients ahead of schedule, the company announced. FPA150 is an antibody that targets ... Read more

October 24, 2018

Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows

News

Ovarian cancer patients with BRCA mutations who received Lynparza (olaparib) maintenance treatment after first-line platinum-based chemotherapy lived three years longer without signs of disease worsening than patients who received a ... Read more

October 22, 2018

First Patient Dosed in Phase 1 Trial of MCY-M11 in Ovarian Cancer, Peritoneal Mesothelioma

News

MaxCyte has begun dosing participants in a Phase 1 trial to assess its lead CAR T-cell therapy, MCY-M11, for the treatment of advanced ovarian cancer and peritoneal mesothelioma patients who failed ... Read more

October 17, 2018

Carrick Acquires Rights to CT900, Plans New Trial in Ovarian Cancer Patients

News

Carrick Therapeutics, a biopharmaceutical company, has acquired the rights to CT900 and plans to conduct a later-stage clinical trial to evaluate the safety and effectiveness of the investigational therapy in ... Read more

October 15, 2018

Tina’s Wish Annual Benefit Dinner Raises $2 Million for Ovarian Cancer Research

News

More than 800 supporters turned out for the 2018 Tina’s Wish Annual Benefit Dinner, raising $2 million for research aimed at ovarian cancer prevention and early detection, the organization announced. ... Read more

October 10, 2018

CT45 Protein Predicts Longer Survival Times in Advanced-stage Ovarian Cancer, Study Reports

News

A protein called CT45 predicts which ovarian cancer patients will respond to platinum-based chemotherapy and is associated with extended survival in these patients, being a new prognostic marker for ovarian ... Read more